Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.
about
Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgeryDoes neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality?Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea.Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomyDoes neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer?Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients.Robot-assisted radical cystectomy.Current Status of Robot-Assisted Radical Cystectomy and Intracorporeal Urinary Diversion.Contemporary update on neoadjuvant therapy for bladder cancer.Neoadjuvant Platinum-Based Chemotherapy is an Independent Predictor for Preoperative Thromboembolic Events in Bladder Cancer Patients Undergoing Radical Cystectomy.Essential Japanese guidelines for the prevention of perioperative infections in the urological field: 2015 edition.Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis.Selecting candidates for early discharge after radical cystectomy for bladder cancer.Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience
P2860
Q28074930-4807C83B-CF29-4662-942A-B943AA0236ABQ35072610-84E41E64-1A36-446F-81DB-7257A1CCB363Q35905142-E3DDD4E7-1A25-40A2-873B-2D29C266E99CQ36823607-E5CB3744-CBA3-4AFE-86B3-FE99AC6F054DQ36923856-AD4998B2-EB69-4DD1-990B-E8F6596E1134Q37626892-A9BC456E-C29A-4695-8DB9-6BF3DB1D9949Q38218163-508A35A5-F70B-4629-AE13-0465FAB6D4F4Q38574487-66C37DED-1116-4DC9-8487-409E65EDC9DBQ38791867-84FC01E8-4BC3-4601-97E8-903DB242FB6FQ39177293-8F34429E-F4DF-4DD1-A640-F90930AAA1C2Q41601417-D06F1C37-7ABB-400C-BCAF-B42528A11A32Q44452224-E73B8A64-1C74-4FDC-891F-2BC26F236805Q45014323-3147E9D9-C8C4-4172-B06F-B9059FFBAABEQ55040059-AFB1712F-8DE5-4FE6-80AD-411F3E489DC3Q57073248-FB142497-3866-42D1-9D65-C56DC835CCD9
P2860
Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Neoadjuvant chemotherapy for b ...... sk of perioperative morbidity.
@ast
Neoadjuvant chemotherapy for b ...... sk of perioperative morbidity.
@en
type
label
Neoadjuvant chemotherapy for b ...... sk of perioperative morbidity.
@ast
Neoadjuvant chemotherapy for b ...... sk of perioperative morbidity.
@en
prefLabel
Neoadjuvant chemotherapy for b ...... sk of perioperative morbidity.
@ast
Neoadjuvant chemotherapy for b ...... sk of perioperative morbidity.
@en
P2093
P2860
P356
P1433
P1476
Neoadjuvant chemotherapy for b ...... sk of perioperative morbidity.
@en
P2093
Angela B Smith
David C Johnson
Eric M Wallen
Matthew E Nielsen
Matthew I Milowsky
Michael E Woods
Raj S Pruthi
P2860
P304
P356
10.1111/BJU.12585
P577
2014-03-14T00:00:00Z